

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
07 May 2020 (07.05.2020)



(10) International Publication Number
WO 2020/087160 A1

(51) International Patent Classification:

C12N 5/10 (2006.01) *C07K 14/51* (2006.01)
A61K 35/12 (2015.01) *C12N 15/18* (2006.01)
A61K 38/18 (2006.01) *C12N 15/55* (2006.01)
A61K 38/46 (2006.01) *C12N 15/85* (2006.01)
A61K 48/00 (2006.01) *C12N 5/0775* (2010.01)
A61P 37/00 (2006.01) *C12N 9/18* (2006.01)
C07K 14/475 (2006.01)

(21) International Application Number:

PCT/CA2019/051526

(22) International Filing Date:

29 October 2019 (29.10.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/752,000 29 October 2018 (29.10.2018) US

(71) Applicants: **OTTAWA HOSPITAL RESEARCH INSTITUTE** [CA/CA]; 501 Smyth Road, Ottawa, Ontario K1H 8L6 (CA). **UNITED THERAPEUTICS CORPORATION** [US/US]; 1040 Spring Street, Sylver Spring, Maryland 20910 (US).

(72) Inventors: **CALLAHAN, Michael**; 4880 Kelso Rd., Boulder, Colorado 80301 (US). **MEI, Shirley H.J.**; 1885 Dauphin Road, Ottawa, Ontario K1G 2L4 (CA). **WANG, Yan**; Unit 409, 1825 Russel Road, Ottawa, Ontario K1G 3T4 (CA). **FLORIAN, Maria**; 212 Spring Garden, Dol-

lard-des-Ormeaux, Québec H9B 2J1 (CA). **ROWE, Kate-lynn**; 147 Keltie Private, Ottawa, Ontario K2J 0A3 (CA). **LEE, Chyan-jang**; 808 Pergola Place, Ottawa, Ontario K1T 0T8 (CA).

(74) Agent: **LAVERY, DE BILLY, L.L.P.**; 1, Place Ville Marie, Bureau 4000, Montréal, Québec H3B 4M4 (CA).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: GENETICALLY-ENGINEERED MESENCHYMAL STEM CELLS OVEREXPRESSING AOA AND USES THEREOF




FIG. 5B

(57) Abstract: Genetically-modified mesenchymal stem cells (MSCs) overexpressing an acyloxyacyl hydrolase (AOAH) polypeptide, such as MSCs comprising a recombinant nucleic acid encoding the AOAH polypeptide, are described. The MSCs may further overexpress a second polypeptide of interest, such as angiopoietin-1 (ANGPT1). Pharmaceutical compositions comprising the genetically-modified MSCs are also described. The use of such genetically-modified MSCs and/or pharmaceutical compositions comprising same as a medicament, for example for the treatment of systemic inflammatory response syndrome (SIRS) or sepsis, is also described.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*